Summary
Methallylescaline, chemically known as 4-Methylallyloxy-3,5-dimethoxyphenethylamine, is a relatively lesser-known psychedelic substance. It serves as the 4-methyl analogue of allylescaline. Alexander Shulgin originally synthesized this compound.
In Shulgin’s book PiHKAL (Phenethylamines I Have Known And Loved), the recommended dosage range for Methallylescaline is noted as 40 to 65 mg, with the effects typically extending throughout 12 to 16 hours. Despite its intriguing properties, there is limited available data regarding the pharmacological characteristics, metabolism, and toxicity of Methallylescaline. However, it is recognized as an agonist of 5-HT2A receptors and has been marketed as a designer drug.
| Identifiers | |
|---|---|
| CAS Number | 207740-41-8 |
| 3D model (JSmol) | Interactive image |
| ChEMBL | ChEMBL126803 |
| ChemSpider | 21106346 |
| PubChemCID | 44350127 |
| UNII | CVN0S9V910 |
| CompTox Dashboard(EPA) | DTXSID20658380 |
Legal status
Since January 26, 2016, Methallylescaline became prohibited in Sweden.
FAQ
1. What is Methallylescaline?
- Methallylescaline is a lesser-known psychedelic compound and is the 4-methyl analogue of allylescaline.
2. How was Methallylescaline first synthesized?
- Alexander Shulgin, a prominent figure in the field of psychopharmacology, initially synthesized Methallylescaline.
3. What is the typical dosage and duration of Methallylescaline effects?
- As per Alexander Shulgin’s PiHKAL, the recommended dosage range for Methallylescaline is approximately 40 to 65 mg, and the effects can last for a duration of 12 to 16 hours.
4. Is Methallylescaline legal in Sweden?
- No, Methallylescaline is illegal in Sweden as of January 26, 2016.
5. Are there any known risks associated with Methallylescaline use?
- Due to limited research, potential risks associated with Methallylescaline use, including psychological distress and adverse effects, should be considered. Responsible use and caution are advised.
6. Can Methallylescaline be used for therapeutic purposes?
- There is limited scientific research on the therapeutic potential of Methallylescaline, and it is not approved for medical or therapeutic use. Other psychedelics have been more extensively studied for therapeutic applications.
7. Is Methallylescaline addictive?
- The addictive potential of Methallylescaline is not well understood. It is generally considered to have a lower risk of physical dependence compared to substances like opioids or stimulants. However, psychological dependence can still occur.
8. Where can I find more information about Methallylescaline?
- Given the evolving legal and scientific landscape surrounding Methallylescaline, it’s crucial to consult reliable sources of scientific literature and seek advice from healthcare professionals. Staying informed and making well-informed decisions is essential when considering the use of this substance.
References
- Anvisa, in their resolution dated July 24, 2023, published “Collegiate Board Resolution No. 804,” which outlines lists of substances falling under special control, including narcotic, psychotropic, precursor, and other substances. This information was documented in Brazilian Portuguese in the Diário Oficial da União (Official Gazette), published on July 25, 2023, and archived until August 27, 2023.
- Details about Methallylescaline can be found in PiHKAL.
- A study conducted by Clare BW in 2002 delved into Quantitative Structure-Activity Relationship (QSAR) of benzene derivatives, comparing classical descriptors, quantum theoretic parameters, and flip regression. This research specifically looked at phenylalkylamine hallucinogens.
- In July 2015, Coelho Neto conducted a study focusing on the rapid detection of NBOME’s and other Novel Psychoactive Substances (NPS) on blotter papers using direct ATR-FTIR spectrometry.
- In November 2015, the Swedish public health agency, Folkhälsomyndigheten, released information regarding the potential classification of 31 new substances as controlled drugs or hazardous materials.